Volver a Agenda
Session 7 Track 1A: The Three D’s of RWE
Session Chair(s)
Ellen Whipple, PHARMD
Owner/Principal Writer, EW Associates, LLC, United States
Donna Booth, PHARMD
Head, Field Medical Accounts-East, US Medical Affairs, GlaxoSmithKline, United States
Real-world data (RWD) and real world evidence (RWE) play an increasing role in healthcare decisions. RWD is derived from multiple sources outside typical clinical research settings, including electronic health records (EHRs), claims and billing data, product and disease registries, and data gathered through personal devices and health applications. RWE is the intersection between the structured rigor of a randomized control trial and the clinical exposure a treatment receives once it enters clinical practice as it is derived from analysis of RWD. Medical information departments vary in their understanding and approach to the 3 D’s (definition, decision makers, and dissemination) of RWE. As the US healthcare system continues to seek value for patients, it is increasingly important to have strategies for addressing RWE across the continuum of decision makers (regulators, payers, HCPs and patients).
Learning Objective : - Define RWE by discussing various types and differentiating from clinical trial data
- Recognize decision makers receiving RWE and describe how RWE brings value based on their unique perspectives
- Propose strategies for dissemination of RWE by sharing examples utilized by various medical information departments that demonstrated success as well as areas for improvement
- Share strategies from audience members regarding dissemination of RWE
Speaker(s)
Real World Evidence: Therapeutic Effectiveness Beyond Efficacy
President and Principal of CERES, Cox Econometric Research, LLC, United States
Sharing the Value of RWE
Medical Information Director, Respiratory US Medical Information, GlaxoSmithKline, United States
Digital Dissemination of RWE: EvidenceFinder
Regional Medical Liaison, Novo Nordisk Inc., United States
¿Tiene una cuenta?